Viral Vitalism

Rapid Briefs

The source-backed signal desk for health stories before they become obvious.

VV catches the signal early, explains it cleanly, shows the source trail, and tells you what not to overclaim.

Filtered signal trail

Tag: peptides

Clear filter
Peptide RegulationDeveloping

FDA Is Reviewing Compounded Peptide-Clinic Favorites

FDA's July advisory meeting covers BPC-157, Semax, Epitalon-related substances, MOTS-c, TB-500, KPV, DSIP/emideltide, and other peptide-related bulk substances popular in longevity circles.

Why now

The FDA calendar puts several longevity-clinic peptide favorites into a formal public regulatory review window.

Overclaim risk
high
Primary source
Official
Published
Jul 5, 2026
Read brief ->
Longevity SafetyDeveloping

FDA Panel Will Review Popular Longevity Peptides Amid Safety and Evidence Concerns

FDA advisers will review whether several popular peptides should be allowed for certain pharmacy compounding uses, while FDA materials flag limited human evidence and potential safety or quality concerns.

Why now

The peptide gray market just got a real FDA spotlight: BPC-157, TB-500, MOTS-c, Semax, and Epitalon are heading into a public review.

Overclaim risk
high
Primary source
Regulatory
Published
Jun 30, 2026
Read brief ->